Moleculin Biotech (NASDAQ:MBRX) Now Covered by StockNews.com
StockNews.com started coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a research report sent to investors on Sunday. The brokerage issued a sell rating on the stock. Separately, Maxim Group lowered their price target on Moleculin Biotech from $20.00 to $8.00 and set a “buy” rating for the company in a research […]
StockNews.com started coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a research report sent to investors on Sunday. The brokerage issued a sell rating on the stock. Separately, Maxim Group lowered their price target on Moleculin Biotech from $20.00 to $8.00 and set a “buy” rating for the company in a research […]
